BioCentury | Oct 27, 2020
Finance

Tumor profiling play Caris to grow biopharma partnerships with $310M round

With a newly raised $310 million in combined equity and debt, Caris plans to scale up its tumor profiling business and expand its biopharma partnerships.  The round, which includes Caris Life Sciences Inc.’s first equity...
BioCentury | Jul 23, 2020
Deals

July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG

BioNTech prices upsized financing BioNTech SE (NASDAQ:BNTX) raised $511.5 million in an upsized offering through the sale of 5.5 million ADSs at $93 per ADS. The deal, which had been slated for 5 million ADSs,...
BioCentury | Jul 23, 2020
Finance

Elevation debuts with tumor-agnostic mAb in Phase II

Led by former Loxo Chairman Steve Elms, Elevation emerged from stealth Tuesday with a registration-enabling trial of a tissue-agnostic cancer therapy and a handful of diagnostics partners. Elevation Oncology Inc. is developing therapies for cancers...
BioCentury | Jul 14, 2020
Deals

Roche deal clears path for Blueprint’s financial independence

...factor (FGF) receptor 4 NTRK1 (TrkA) - Neurotrophic tyrosine kinase receptor 1 NRTK2 (TrkB) - Neurotrophic tyrosine kinase receptor 2...
BioCentury | Jul 7, 2020
Deals

Adding to targeted oncology portfolio, Zai gains China rights to Turning Point’s repotrectinib

...1 receptor tyrosine kinase TrkA (NTRK1) - Neurotrophic tyrosine kinase receptor 1 TrkB (NTRK2) - Neurotrophic tyrosine kinase receptor 2...
BioCentury | Jun 2, 2020
Regulation

June 1 Quick Takes: CHMP recommendations, plus FDA action on AbbVie-Neurocrine, Shionogi, AZ, Lilly, Genentech

CHMP backs Ebola vaccine, targeted cancer therapies EMA’s CHMP recommended approval of a two-component Ebola vaccine -- Zabdeno and Mvabea -- from Johnson & Johnson (NYSE:JNJ) Friday. The agency also backed two targeted cancer therapies:...
BioCentury | Jan 1, 2020
Company News

Fewer FDA approvals in 2019, but a basket of firsts

...TOP1 - Topoisomerase I; TrkA (NTRK1) - Neurotrophic tyrosine kinase receptor 1 TrkB (NTRK2) - Neurotrophic tyrosine kinase receptor 2...
BioCentury | Oct 3, 2019
Targets & Mechanisms

Blocking the MAPK pathway for Trk inhibitor resistant cancers

...ERK) - MAP kinase; TrkA (NTRK1) - Neurotrophic tyrosine kinase receptor 1; TrkB (NTRK2) - Neurotrophic tyrosine kinase receptor 2...
...3 Hongjiang Li, Staff Writer Vitrakvi, larotrectinib (LOXO-101) Rozlytrek, entrectinib (RG6268, rxdx-101) Roche Bayer AG Neurotrophic tyrosine kinase receptor 1 (TrkA) (NTRK1) Neurotrophic tyrosine kinase receptor 2...
BioCentury | Sep 25, 2019
Company News

Sept. 24 Company Quick Takes: FDA approves smallpox vaccine; plus Epidyolex, Vitrakvi, Oral semaglutide, Takeda-Evotec, Guerbet-IBM Watson

...Sodium-glucose cotransporter 2; TrkA (NTRK1) - Neurotrophic tyrosine kinase receptor 1; TrkB (NTRK2) - Neurotrophic tyrosine kinase receptor 2...
BioCentury | Sep 16, 2019
Financial News

Sept. 6 Financial Quick Takes: Turning Point, uniQure raise follow-ons; plus Autolus, Frequency, ADC

...1 receptor tyrosine kinase; TrkA (NTRK1) - Neurotrophic tyrosine kinase receptor 1; TrkB (NTRK2) - Neurotrophic tyrosine kinase receptor 2...
...Management Anaplastic lymphoma kinase (ALK) c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1) Neurotrophic tyrosine kinase receptor 1 (TrkA) (NTRK1) Neurotrophic tyrosine kinase receptor 2...
Items per page:
1 - 10 of 206